Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 5/2013

01.09.2013 | Original Article

Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease

verfasst von: Markus Niemann, Tanja Hartmann, Mehdi Namdar, Frank Breunig, Meinrad Beer, Wolfram Machann, Sebastian Herrmann, Georg Ertl, Christoph Wanner, Frank Weidemann

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Morphology and function of Fabry cardiomyopathy has been previously studied by echocardiography and cardiac magnetic resonance (CMR). However, the value of electrocardiography (ECG) in relation to these two techniques remains largely unknown.

Methods

One hundred fifty genetically confirmed Fabry patients were investigated using a comprehensive clinical workup comprising 12-lead ECG, echocardiography, and CMR.

Results

ECG parameters at rest [PR, P wave, QT, QTc, QT dispersion and time interval from the peak to the end of the T wave (Tpeak to Tend)] were normal in the entire cohort and did not distinguish between males and females or stages of cardiomyopathy. A significant positive correlation was found between left ventricular (LV) mass on CMR and both the QRS duration and the LV Sokolow index, with the highest values in male patients with an advanced cardiomyopathy stage. No prediction of late enhancement on CMR (a sign for replacement fibrosis) was possible by a single ECG parameter. However, the absence of ST or T alterations (in 37 of 38 patients) specifically excluded late enhancement on CMR.

Conclusion

Our data in a large cohort of Fabry patients, including all cardiomyopathy stages, show, in contrast to former assumptions, that ECG parameters are not suitable to stage Fabry cardiomoypathy. Most ECG parameters were normal in the complete cohort. However, the absence of ST or T alterations seems to almost exclude late enhancement on CMR in these patients.
Literatur
Zurück zum Zitat Alfakih K, Reid S, Jones T, Sivananthan M (2004) Assessment of ventricular function and mass by cardiac magnetic resonance imaging. Eur Radiol 10:1813–1822 Alfakih K, Reid S, Jones T, Sivananthan M (2004) Assessment of ventricular function and mass by cardiac magnetic resonance imaging. Eur Radiol 10:1813–1822
Zurück zum Zitat Breunig F, Weidemann F, Beer M et al (2003) Fabry disease: diagnosis and treatment. Kidney Int Suppl 84:S181–S185CrossRef Breunig F, Weidemann F, Beer M et al (2003) Fabry disease: diagnosis and treatment. Kidney Int Suppl 84:S181–S185CrossRef
Zurück zum Zitat Cain PA, Ahl R, Hedstrom E et al (2009) Age and gender specific normal values of left ventricular mass, volume and function for gradient echo magnetic resonance imaging: a cross sectional study. BMC medical imaging 2. Cain PA, Ahl R, Hedstrom E et al (2009) Age and gender specific normal values of left ventricular mass, volume and function for gradient echo magnetic resonance imaging: a cross sectional study. BMC medical imaging 2.
Zurück zum Zitat Chimenti C, Morgante E, Tanzilli G et al (2008) Angina in fabry disease reflects coronary small vessel disease. Circ Heart Fail 3:161–169CrossRef Chimenti C, Morgante E, Tanzilli G et al (2008) Angina in fabry disease reflects coronary small vessel disease. Circ Heart Fail 3:161–169CrossRef
Zurück zum Zitat Desnick R, Ionnou Y, Eng C (1995) Fabry disease: alpha galactosidase A deficiency. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 2741–2784 Desnick R, Ionnou Y, Eng C (1995) Fabry disease: alpha galactosidase A deficiency. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 2741–2784
Zurück zum Zitat Eng CM, Banikazemi M, Gordon RE et al (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 3:711–722CrossRef Eng CM, Banikazemi M, Gordon RE et al (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 3:711–722CrossRef
Zurück zum Zitat Eng CM, Germain DP, Banikazemi M et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 9:539–548CrossRef Eng CM, Germain DP, Banikazemi M et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 9:539–548CrossRef
Zurück zum Zitat Hughes DA, Elliott PM, Shah J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2:153–158CrossRef Hughes DA, Elliott PM, Shah J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2:153–158CrossRef
Zurück zum Zitat Kampmann C, Wiethoff CM, Martin C et al (2002) Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 439:21–27CrossRef Kampmann C, Wiethoff CM, Martin C et al (2002) Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 439:21–27CrossRef
Zurück zum Zitat Linhart A, Lubanda JC, Palecek T et al (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 75–83; discussion 65. Linhart A, Lubanda JC, Palecek T et al (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 75–83; discussion 65.
Zurück zum Zitat Mehta J, Tuna N, Moller JH, Desnick RJ (1977) Electrocardiographic and vectorcardiographic abnormalities in Fabry’s disease. Am Hear J 6:699–705CrossRef Mehta J, Tuna N, Moller JH, Desnick RJ (1977) Electrocardiographic and vectorcardiographic abnormalities in Fabry’s disease. Am Hear J 6:699–705CrossRef
Zurück zum Zitat Mehta A, Clarke JT, Giugliani R et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 8:548–552CrossRef Mehta A, Clarke JT, Giugliani R et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 8:548–552CrossRef
Zurück zum Zitat Moon JC, Sachdev B, Elkington AG et al (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 23:2151–2155CrossRef Moon JC, Sachdev B, Elkington AG et al (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 23:2151–2155CrossRef
Zurück zum Zitat Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ (2006) The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 3:479–482CrossRef Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ (2006) The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 3:479–482CrossRef
Zurück zum Zitat Namdar M, Kampmann C, Steffel J et al (2010) PQ interval in patients with Fabry disease. Am J Cardiol 5:753–756CrossRef Namdar M, Kampmann C, Steffel J et al (2010) PQ interval in patients with Fabry disease. Am J Cardiol 5:753–756CrossRef
Zurück zum Zitat Namdar M, Steffel J, Vidovic M et al (2011) Electrocardiographic changes in early recognition of Fabry disease. Heart 6:485–490CrossRef Namdar M, Steffel J, Vidovic M et al (2011) Electrocardiographic changes in early recognition of Fabry disease. Heart 6:485–490CrossRef
Zurück zum Zitat Niemann M, Breunig F, Beer M et al (2010) The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 23:1915–1919CrossRef Niemann M, Breunig F, Beer M et al (2010) The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 23:1915–1919CrossRef
Zurück zum Zitat Niemann M, Herrmann S, Hu K et al (2011) Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 6:592–601CrossRef Niemann M, Herrmann S, Hu K et al (2011) Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 6:592–601CrossRef
Zurück zum Zitat Roudebush CP, Foerster JM, Bing OH (1973) The abbreviated PR interval of Fabry’s disease. N Engl J Med 7:357–358CrossRef Roudebush CP, Foerster JM, Bing OH (1973) The abbreviated PR interval of Fabry’s disease. N Engl J Med 7:357–358CrossRef
Zurück zum Zitat Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 21:2743–2749CrossRef Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 21:2743–2749CrossRef
Zurück zum Zitat Shah JS, Hughes DA, Sachdev B et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 6:842–846CrossRef Shah JS, Hughes DA, Sachdev B et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 6:842–846CrossRef
Zurück zum Zitat Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med Off J Am Coll Med Genet 11:790–796 Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med Off J Am Coll Med Genet 11:790–796
Zurück zum Zitat Weidemann F, Breunig F, Beer M et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 11:1299–1301CrossRef Weidemann F, Breunig F, Beer M et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 11:1299–1301CrossRef
Zurück zum Zitat Weidemann F, Breunig F, Beer M et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 12:1221–1227CrossRef Weidemann F, Breunig F, Beer M et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 12:1221–1227CrossRef
Zurück zum Zitat Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 4:524–529CrossRef Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 4:524–529CrossRef
Zurück zum Zitat Whybra C, Miebach E, Mengel E et al (2009) A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 6:441–449CrossRef Whybra C, Miebach E, Mengel E et al (2009) A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 6:441–449CrossRef
Zurück zum Zitat Xia Y, Liang Y, Kongstad O, Holm M, Olsson B, Yuan S (2005) Tpeak-Tend interval as an index of global dispersion of ventricular repolarization: evaluations using monophasic action potential mapping of the epi- and endocardium in swine. J Interv Card Electrophysiol 2:79–87CrossRef Xia Y, Liang Y, Kongstad O, Holm M, Olsson B, Yuan S (2005) Tpeak-Tend interval as an index of global dispersion of ventricular repolarization: evaluations using monophasic action potential mapping of the epi- and endocardium in swine. J Interv Card Electrophysiol 2:79–87CrossRef
Metadaten
Titel
Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease
verfasst von
Markus Niemann
Tanja Hartmann
Mehdi Namdar
Frank Breunig
Meinrad Beer
Wolfram Machann
Sebastian Herrmann
Georg Ertl
Christoph Wanner
Frank Weidemann
Publikationsdatum
01.09.2013
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 5/2013
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-012-9540-8

Weitere Artikel der Ausgabe 5/2013

Journal of Inherited Metabolic Disease 5/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.